Restricted accessOtherFirst published online 2002-1
Patient-Reported Outcomes: The Example of Health-Related Quality of Life—A European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process
The added value for assessing the health-related quality of life (HRQOL) in chronic conditions is now well documented for evaluation of treatment effectiveness in clinical trials and as a criterion for licensing new medications and in policy decisions. However, European standards still need to be developed for the measurement and reporting of HRQOL in clinical trials. This is one of the objectives of the European Regulatory Issues on Quality of Life Assessment (ERIQA) Working Group. This document reviews the major issues arising from the selection of an HRQOL instrument; the integration of HRQOL assessment into the research protocol (methodological design, practicalities of HRQOL administration and collection, prevention and handling of missing data); the statistical analysis plan; and the presentation and interpretation of the results. Finally, to gain wider acceptance, whether HRQOL is considered as a primary or secondary endpoint, the scientific principles of clinical trial design should apply to HRQOL.
JohnsonJRTempleR.Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep.1985;69:1155–1159.
2.
LohrKNAaronsonNKAlonsoJBumamMAPatrickDLPerrinEBRobertsJSEvaluating quality-of-life and health status instruments: Development of scientific review criteria. Clin Ther.1996;18:979–992.
3.
Scientific Advisory Committee.Instrument Review Criteria. Med Outcomes Trust Bull.1995;3:I–IV.
4.
StaquetMBerzonROsobaDMachinD.Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res.1996;5:496–500.
5.
FayersPMHopwoodPHarveyAGirlingDJMachinD, Stephens R, on Behalf of the MRS Cancer Trials Office. Quality of Life Assessment in Clinical Trials—Guidelines and a Checklist for Protocol Writers: The UK Medical Research Council Experience. Eur J Cancer.1997;33:20–28.
6.
RevickiDALeidyNKGenesteB.Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health.1999;2:113–127.
7.
SmithN.Quality of life studies from the perspective of an FDA reviewing statistician. Drug Inf J.1993;27:617–623.
8.
SandersCEggerMDonovanJTalionDFrankelS.Reporting on quality of life in randomised controlled trials: Bibliographic study. Br Med J.1998;317:1191–1194.
9.
ChassanyOBergmannJFCaulinC.Reporting on quality of life in randomised controlled trials. Br Med J.1999;318:1142.
10.
KongSXGandhiSKMethodologic assessments of quality of life measures in clinical trials. Ann Pharmacother.1997;31:830–836.
11.
BrownRSStrategies and pitfalls in quality of life research. Hepatology.1999;29(Suppl. 1):9S–12S.
12.
de HaesJCurranDYoungTBottomleyAFlechtnerHAaronsonNBlazebyJBjordalKBrandbergYGreimelEMaherJSprangersMCullA.Quality of life evaluation in oncological clinical trials—the EORTC model. The EORTC quality of life study group. Eur J Cancer.2000;36:821–825.
SchipperHClinchJPowellV.Definition and Conceptual Issues. In: SpilkerB, ed. Quality of Life Assessments in Clinical Trials.New York, NY: Raven Press; 1990:11–24.
15.
SpitzerWOState of science 1986: Quality of life and functional status as target variables for research. J Chronic Diseases.1987;6:465–471.
16.
SullivanMKarlssonJTaftC.How to Assess Quality of Life in Medicine: Rationale and Methods. In: Guy-GrandBAilhaudG, eds. Progress in Obesity Research:8.London: Libbey; 1999:749–755.
17.
World Health Organization.World Health Organization Constitution. Basic Documents.Geneva, Switzerland: World Health Organization; 1948.
18.
PatrickDLEricksonP.Health Status and Health Policy: Allocating Resources to Health Care.New York, NY: Oxford University Press; 1993.
19.
BurkeL.Acceptable evidence for pharmaceutical advertising and labeling, DIA Workshop on Pharmacoeconomic and Quality of Life Labeling and Marketing Claims, October 3, 2000, New Orleans, LA.
20.
AaronsonNKQuality of life assessment in clinical trials: Methodologic issues. Control Clin Trials.1989;10:S195–S208.
21.
TestaMASimonsonDCAssessment of quality of life outcomes. N Engl J Med.1996;334:835–840.
22.
RevickiDAEhrethJLHealth-related quality-of-life assessment and planning for the pharmaceutical industry. Clin Ther.1997;19:1101–1115.
BulpittCJFletcherAEThe measurement of quality of life in hypertensive patients: A practical approach. Br J Clin Pharmacol.1990;30:353–364.
25.
WiklundIDimenäsEWahlM.Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials.1990;11:169–179.
26.
WiklundI.Aspects of quality of life in gastrointestinal disease: Some methodological issues. Scand J Gastroenterol.1995;208:129–132.
27.
TrusTLLaycockWSBranumGDWaringJPHunterJGQuality of life scores correlate poorly with subjective and objective measurements of gastroesophageal reflux. Gastroenterol.1997;112:A1480.
28.
GuyattGHThompsonPJBermanLBSullivanMJTownsendMJonesNLPugsleySOHow should we measure function in patients with chronic heart and lung disease?J Chronic Diseases.1985;38:517–524.
29.
RectorTSKuboSHCohnJNPatients' Self-assessment of their cognitive heart failure: II: Content, reliability and validity of a new measure. The Minnesota Living with Heart Failure Questionnaire. Heart Failure.1987;3:198–209.
30.
JuniperEFGuyattGHFerriePJGriffithLEMeasuring quality of life in asthma. Am Rev Respir Dis.1993;147:832–838.
31.
WiklundIComerfordMBDimenasE.The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol.1991;14:204–208.
32.
GuyattGHFeenyDHPatrickDLMeasuring Health-related quality of life. Ann Int Med.1993;118:622–629.
33.
StewartALGreenfieldSHaysRDWellsKRogersWHBerrySDMcGlynnEAWareJEFunctional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA.1989;262:907–913.
34.
BaylissMSGandekBBungayKMSuganoDHsuMAWareJEA questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res.1998;7:39–55.
35.
GanzPACoscarelliAFredCKahnBPlinskiMLPetersenL.Breast cancer survivors: Psychological concerns and quality of life. Breast Cancer Res Treat.1996;38:183–199.
36.
FletcherAGoreSJonesDFiztpatrickRSpiegel-HalterDCoxD.Quality of life measures in health care. II: Design, analysis, and interpretation. Br Med J.1992;305:1145–1148.
37.
GillTMFeinsteinARA critical appraisal of the quality of quality of life measurements. JAMA.1994;272:619–626.
38.
PatrickDLDeyoRAGeneric and disease-specific measures in assessing health status and quality of life. Med Care.1989;27(Suppl 3):S217–S232.
39.
GoldsteinRSGortEHGuyattGHStubbingDAvendanoMAProspective randomized controlled trial of respiratory rehabilitation. Lancet.1994;344:1394–1397.
40.
TandonPKStanderHSchwarzRPJAnalysis of quality of life data from a randomized, placebo controlled heart-failure trial. J Clin Epidemiol.1989;42:955–962.
41.
LaupacisAWongCChurchillD.The use of generic and specific quality-of-life measures in hemodialysis patients treated with Erythropoietin. Control Clin Trials.1991;121:68S–79S.
42.
GalmicheJPBarthelemyPHamelinB.Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of Omeprazole and Cisapride. Aliment Pharmacol Ther.1997;11:765–773.
43.
TarterRESwitalaJArriaAPlailJVan ThielD.Quality of life before and after orthotopic hepatic transplantation. Arch Int Med.1991;151:1521–1526.
44.
ChassanyOMarquisPScherrerBReadNWFingerTBergmannJFFraitagBGeneveJCaulinC.Validation of a specific quality of life questionnaire in Functional Digestive Disorders (FDDQL). Gut.1999;44:527–533.
45.
BergnerMRothmanMLHealth status measures: An overview and guide for selection. Ann Rev Public Health.1987;8:191–210.
46.
WiklundI.Quality of life and regulatory issues. Scand J Gastroenterol.1996;31(Suppl. 221):37–38.
47.
TestaMANackleyJFMethods for quality-of-life studies. Ann Rev Public Health.1994;15:535–559.
48.
GuyattGHKirshnerBJaeschkeR.Measuring health status: What are the necessary measurement properties?J Clin Epidemiol.1992;45:1341–1345.
49.
HaysRAndersonRRevickiDAAssessing Reliability and Validity of Measurement in Clinical Trials. In: StaquetMJHaysRDFayersPM, eds. Quality of Life Assessment in Clinical Trials.New York, NY: Oxford University Press; 1998: 169–182.
50.
FletcherA.Quality-of-life measurements in the evaluation of treatment: Proposed guidelines. Br J Clin Pharmacother.1995;39:217–222.
51.
MarquisPFayolCJoireJELeplègeA.Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Qual Life Res.1995;4:540–546.
52.
JenkinsonCZieblandSFitzpatrickRMowatA.Sensitivity to change of weighted and unweighted versions of two health status measures. Intl J Health Sciences.1991;2:189–194.
53.
ZimmermanM.Weighted versus unweighted life event scores: Is there a difference?J Human Stress.1983;9:30–35.
54.
FitzpatrickRFletcherAGoreSJonesDSpiegelhalterDCoxD.Quality of life measures in health care. I: Applications and issues in assessment. Br Med J.1992;305:1074–1077.
55.
KirschnerBGuyattGHA methodologic framework for assessing health indices. J Chronic Diseases.1985;38:27–36.
56.
GuyattGMitchellAIrvineEJSingerJWilliamsNGoodacreRTompkinsC.A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterol.1989;96:804–810.
57.
EypaschEWilliamsJIWood-DauphineeSUreBMSchmüllingCNeugebauerETroidlH.Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg.1995;82:216–222.
58.
ScharlooMKapteinAAWeinmanJAWillemsLNARooijmansHGMPhysical and psychological correlates of functioning in patients with chronic obstructive pulmonary disease. J Asthma.2000;37:17–29.
59.
FallerHBulzebruckHDringsPLangH.Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry.1999;56:756–762.
60.
StockierMROsobaDCoreyPGoodwinPJTannockIFConvergent, discriminative, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with Analogous Scales Form the EORTC QLQ-C30 and a trial-specific module. J Clin Epidemiol.1999;52:653–666.
61.
FeaganBGMcDonaldJWRochonJLaupacisAFedorakRNKinnearDSaibilFGrollAArchambaultAGilliesRValbergB, Irvine JE, for the Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose Cyclosporine for the treatment of Crohn's Disease. N Engl J Med.1994;330:1846–1851.
62.
GuyattGHWalterSNormanG.Measuring health status over time. Assessing the usefulness of evaluative instruments. J Chronic Diseases.1987;40:171–178.
63.
KazisLEAndersonJJMeenanRFEffect sizes for interpreting changes in health status. Med Care.1989;27(Suppl. 3):S178–S189.
64.
DeyoRADiehrPPatrickDLReproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials.1991;12:S142–S158.
65.
AcquadroCJambonBEllisDMarquisP.Languages and Translation Issues. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials.Second edition. Philadelphia, PA: Lippincott-Raven Publishers; 1996:575–585.
66.
BullingerMAndersonRCeliaDAaronsonN.Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res.1993;2:451–459.
67.
HuntSMCross-cultural Issues in the Use of Quality of Life Measures in Randomized Clinical Trials. In: StaquetMJHaysRDFayersPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice.New York, NY: Oxford University Press; 1998: 51–67.
68.
BullingerMAlonsoJApoloneGLeplegeASullivanMWood-DauphineeSGandekBWagnerAAaronsonNBechPFukuharaSKaasaSWareJEJr.Translating health status questionnaires and evaluating their quality: The IQOLA project approach. International Quality of Life Assessment. J Clin Epidemiol.1998;51:913–923.
69.
GuilleminFBombardierCBeatonD.Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol.1993;46:1417–1432.
70.
GandekBWareJEJrAaronsonNKAlonsoJApoloneGBjornerJBBrazierJBullingerMFukuharaSKaasaSLeplegeASullivanM.Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA project. J Clin Epidemiol.1998;51:1149–1158.
71.
SpilkerB.Quality of Life Trials. In: SpilkerB, ed. Guide to Clinical Trials.New York, NY: Raven Press; 1991:370–378.
72.
BernhardJCeliaDFCoatesCAFallowfieldLGanzPAMoinpourCMMosconiPOsobaDSimesJHürnyC.Missing quality data in cancer clinical trials: Serious problems and challenges. Stat Med.1998;17:517–532.
73.
OsobaD.Rationale for the timing of health-related quality-of-life assessments in oncological palliative therapy. Cancer Treat Rev.1996;22(Suppl. A):69–73.
74.
RothmanMLHedrickSCBulcroftKAHickamDHRubensteinLZThe validity of proxy-generated scores as measures of patient health status. Med Care.1991;29:115–124.
75.
SneeuwKCAAaronsonNKOsobaDMullerMJHsuMAYungWKBradaMNewlandsESThe use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care.1997;35:490–506.
76.
SprangersMAGAaronsonNKThe role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review. J Clin Epidemiol.1992;45:743–760.
77.
TestaMAHollenbergNKAndersonRBWilliamsGHAssessment of quality of life by patient and spouse during antihypertensive therapy with Atenolol and Nifedipine gastrointestinal therapeutic system. Am J Hypertens.1991;4:363–373.
78.
MathiasSDBatesMMPastaDJCisternasMGFeenyDPatrickDLUse of the health utilities index with stroke patients and their caregivers. Stroke.1997;28:1888–1894.
79.
SneeuwKCAAaronsonNKSprangersMAGDetmarSBWeverLDVSchornagelJHValue of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol.1997;15:1206–1217.
80.
SneeuwKCAAaronsonNKde HaanRJLimburgM.Assessing quality of life after stroke. The value and limitations of proxy ratings. Stroke.1997;28:1541–1549.
81.
StephensRJHopwoodPGirlingDJMachinD.Randomized trials with quality of life endpoints. Are doctor's ratings of patients' physical symptoms interchangeable with patients' self-ratings?Qual life Res.1997;6:225–236.
82.
SimesRJGreatorexVGebskiVJPractical approaches to minimize problems with missing quality of life data. Stat Med.1998;17:725–737.
LydickEEpsteinRSClinical Significance of Quality of Life Data. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials.Philadelphia, PA: Lippincott-Raven Publishers; 1996:461–465.
85.
ChassanyODuracinskyM.Ethics and clinical trials. Fundam Clin Pharmacol.1999;13:437–444.
86.
RushDRStelmachJYoungTLKirchdoeferLJScott-LennoxJHolversonHESabesinSMNicholasTAClinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: A clinical experience network (CEN) Study. J Fam Pract.1995;41:126–136.
87.
JuniperEFQuality of life questionnaires: Does statistically significant = clinically important?J Allergy Clin Immunol.1998;102:16–17.
88.
LydickEEpsteinRSInterpretation of quality of life changes. Qual Life Res.1993;2:221–226.
89.
OfferhausL.Measurement of the quality of life in clinical trials: In pursuit of the unapproachable. Eur J Clin Pharmacol.1991;40:205–208.
90.
CurranDFayersPMMolengerghsGMachinD.Analysis of Incomplete Quality of Life Data in Clinical Trials. In: StaquetMJHaysRDFayersPM, eds. Quality of Life Assessment in Clinical Trials.New York, NY: Oxford University Press; 1998:249–280.
91.
FaircloughDPetersonHCeliaDBonomiP.Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med.1998;17:781–796.
92.
HaydenKAMoinpourCMMetchBFeiglPO'BrianRMGreenSOsborneCKPitfalls in quality of life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum.1993;20:1415–1419.
93.
OlschewskiM.Compliance with QoL assessment in multicentre German breast cancer trials. Stat Med.1998;17:571–575.
94.
WiklundIJunghardOGraceETalleyNJKammMvan ZantenVeldhuyzen SParéPChibaNLeddinDSBigardMAColinRSchoenfeldP.Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg.1998;83(Suppl. 583):41–49.
95.
MachinDWeedenS.Suggestions for the presentation of quality of life data from clinical trials. Stat Med.1998;17:711–724.
96.
TroxelABFaircloughDLCurranDHahnEAStatistical analysis of quality of life with missing data in cancer clinical trials. Stat Med.1998;17:517–532.
97.
FaircloughDLGelberRDQuality of Life: Statistical Issues and Analysis. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials.Philadelphia, PA: Lippincott-Raven Publishers; 1996:427–435.
98.
GuyattGHJuniperEFWalterSDGriffithLEGoldsteinRSInterpreting treatment effects in randomised trials. Br Med J.1998;316:690–693.
99.
JaeschkeRSingerJGuyattGHMeasurement of Health Status: Ascertaining the Minimal Clinically Important Difference. Control Clin Trials.1989;10:407–415.
100.
OsobaDRodriguesGMylesJZeeBPaterJ.Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol.1998;16:139–144.
101.
JuniperEFGuyattGHWillanAGriffithLEDetermining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol.1994;47:81–87.
102.
MahajanPPearlmanDOkamotoL.The effect of Fluticasone Propionate on functional status and sleep in children with asthma and on the quality of life of their parents. J Allergy Clin Immunol.1998;102:19–23.
103.
SamsaGEdelmanDRothmanMLWilliamsGRLipscombJMatcharD.Determining clinically important differences in health status measures. PharmacoEconomics.1999;15:141–155.
104.
WyrwichKWNienaberNATierneyWMWolinskyFDLinking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care.1999;37:469–478.
105.
WareJESnowKKKosinskiMGandekB.SF-36 Health Survey: Manual and Interpretation Guide.Boston, MA: The Health Institute, New England Medical Center; 1993.
106.
ThompsonMSReadJLHutchingsHCPatersonMHarrisEDThe cost effectiveness of Auranofin: Results of a randomized clinical trial. J Rheumatol.1988;15:35–42.
107.
WareJEKellerSDInterpreting General Health Measures. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials.Philadelphia, PA: Lippincott-Raven Publishers; 1996:445–460.
108.
CookRJSackettDLThe number needed to treat: A clinically useful measure of treatment effect. Br Med J.1995;310:452–454.
109.
AltaianDGConfidence intervals for the number needed to treat. Br Med J.1998;317:1309–1312.
110.
JuniperEFThe value of quality of life in asthma. Eur Respir Rev.1997;49:333–337.
111.
LiardFBenichouACGamandSLehertP.The effects of Naftidrofuryl on quality of life. Disease Manage Health Outcomes.1997;2(Suppl. 1):71–78.
112.
AltmanDGBlandJMAbsence of evidence is not evidence of absence. Br Med J.1995;311:485–486.
